Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer

PURPOSE: Third-generation epidermal growth factor receptor (EGFR) inhibitors like nazartinib are active against EGFR mutation–positive lung cancers with T790M-mediated acquired resistance to initial anti-EGFR treatment, but some patients have mixed responses. METHODS: Multiple serial tumor and liqui...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:JCO Precis Oncol
Główni autorzy: Piotrowska, Zofia, Hazar-Rethinam, Mehlika, Rizzo, Coleen, Nadres, Brandon, Van Seventer, Emily E., Shahzade, Heather A., Lennes, Inga T., Iafrate, Anthony J., Dias-Santagata, Dora, Leshchiner, Ignaty, Jessop, Nicholas A., Hu, Haichuan, Digumarthy, Subba R., Nagy, Rebecca J., Lanman, Richard B., Moody, Susan, Niederst, Matthew J., Engelman, Jeffrey A., Hata, Aaron N., Corcoran, Ryan B., Sequist, Lecia V.
Format: Artigo
Język:Inglês
Wydane: American Society of Clinical Oncology 2018
Hasła przedmiotowe:
Original Report
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6097183/
https://ncbi.nlm.nih.gov/pubmed/30123863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.17.00263
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy